美国 · 平台与数据 · TipRanks

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

来源：TipRanks · 美国 9 小时前

详细摘要

Luye Pharma Group ( ($HK:2186) ) has shared an update. Ruoxinlin, approved in China in November 2022 and first included in the reimbursement list in November 2024, ...

在 TipRanks 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.tipranks.com)

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

详细摘要

推荐阅读

Want to Invest in Top Growth Stocks Like Amazon, Apple, and Microsoft but Avoid Nvidia? Consider This Low-Cost Vanguard ETF That’s Up 24.8% This Year.

ANI Pharmaceuticals president & CEO Lalwani sells $383,400 in shares

Bitcoin Faces Final Capitulation Risk: Could $40,000 Be Next?

He Hears Anthropic CEO Predicts AI Could Cure Cancer and Alzheimer’s Within 10 Years. He’s Skeptical, and Medicare May Cover the Clinical Trial Without Paying for the ...

Nvidia earnings collide with Fed’s biggest AI challenge under Warsh

What To Expect In Markets This Week: NVDA, PANW, DIS, HD, TGT, WMT, GRRR Earnings, Kevin Warsh Speech And More

Luye Pharma’s Ruoxinlin Renewed in China’s 2026 Reimbursement Drug List

详细摘要

分享

推荐阅读

Want to Invest in Top Growth Stocks Like Amazon, Apple, and Microsoft but Avoid Nvidia? Consider This Low-Cost Vanguard ETF That’s Up 24.8% This Year.

ANI Pharmaceuticals president & CEO Lalwani sells $383,400 in shares

Bitcoin Faces Final Capitulation Risk: Could $40,000 Be Next?

He Hears Anthropic CEO Predicts AI Could Cure Cancer and Alzheimer’s Within 10 Years. He’s Skeptical, and Medicare May Cover the Clinical Trial Without Paying for the ...

Nvidia earnings collide with Fed’s biggest AI challenge under Warsh

What To Expect In Markets This Week: NVDA, PANW, DIS, HD, TGT, WMT, GRRR Earnings, Kevin Warsh Speech And More